Proton pump inhibitors for peptic ulcer disease, esophagitis or gastroesophageal reflux disease at full therapeutic dosage for >8 weeks |
10 (21.7) |
14.1 |
Calcium channel blockers with chronic constipation |
6 (13.0) |
8.5 |
Aspirin with no history of coronary, cerebral or peripheral vascular symptoms or occlusive event |
4 (8.7) |
5.6 |
Use of aspirin and warfarin in combination without histamine H2-receptor antagonist or proton pump inhibitor |
4 (8.7) |
5.6 |
Tricyclic antidepressants with an opiate or calcium channel blocker |
4 (8.7) |
5.6 |
Aspirin at doses >150 mg/day |
3 (6.5) |
4.2 |
Alpha-blockers in males with frequent incontinence (i.e., 1 or more episodes of incontinence daily) |
3 (6.5) |
4.2 |
Neuroleptic drugs in those with recurrent falls (≥1 fall in past 3 months) |
3 (6.5) |
4.2 |
Long-term opiates in those with recurrent falls (≥1 fall in past 3 months) |
3 (6.5) |
4.2 |
Any duplicate drug class prescription |
3 (6.5) |
4.2 |